ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726

Its studies are mostly in Carcinoma, Hepatocellular, led by Compass Therapeutics.

Furthest: phase 1, since Feb 12, 20261 company-led study, 1 open or runningNext primary completion: Apr 1, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Compass Therapeutics11 open or runningphase 1since Feb 12, 2026Feb 12, 2026Apr 1, 2028phase 1 · NCT07419841

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2026First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT07419841 · 70 planned · United States

Ahead

  1. Apr 1, 2028Primary completion: phase 1 study in Carcinoma, HepatocellularNCT07419841

TargetBeta

PDCD1 →VEGFA →read by rule
“A tetravalent bispecific antibody consisting of a Fc-silenced, immunoglobulin G1 (IgG1) antibody targeting human vascular endothelial growth factor A (VEGF-A), and single chain variable fragment (scFv) targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1;”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07419841Carcinoma, Hepatocellular · United States1RecruitingApr 1, 202870

How it is read

Names in the registry

  • “CTX-10726”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.